Ralimetinib is a Selective and Oral Active p38 MAPK Inhibitor with Antitumor Activity
Nowadays, cancer has become no stranger to people. We mentioned it many times in our blogs. p38 MAPK (p38 mitogen-activated protein kinase) are a group of kinases responsive to stress stimuli.…